Clarent Biopharma, Inc.
Clinical trials sponsored by Clarent Biopharma, Inc., explained in plain language.
-
New pill RAP-103 aims to clear psoriasis in 8 weeks
Disease control Recruiting nowThis Phase 2 trial tests whether the oral drug RAP-103 can improve skin clearance and quality of life in people with moderate to severe psoriasis. About 90 adults aged 18 to 70 will take either a daily or twice-daily dose of RAP-103 or a placebo for 8 weeks. The study measures ho…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to cut opioid use after joint replacement surgery
Symptom relief Recruiting nowThis study tests whether a new drug called CBP-0276 can help people who have had hip or knee replacement surgery use fewer opioid painkillers. Participants take either CBP-0276 or a placebo alongside standard oxycodone for 28 days after surgery. The goal is to see if CBP-0276 red…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC